{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T22:10:18Z","timestamp":1782252618612,"version":"3.54.5"},"reference-count":60,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Childhood-onset systemic lupus erythematosus (cSLE, also known as juvenile or paediatric SLE) is a severe autoimmune disease affecting multiple organs and systems, with higher morbidity and severity compared to adult SLE (aSLE). The European Union\u2019s Paediatric Regulation No. 1901\/2006 mandates the agreement of a paediatric investigation plan (PIP) for new investigational medicinal products (IMPs) to ensure reliable efficacy and safety data for paediatric indications. This study examined the experience of the Paediatric Committee (PDCO) at the European Medicines Agency (EMA) in assessing PIPs for cSLE, highlighting the challenges and potential solutions in the planning of development of novel agents in this disease and providing the academia point of view on key points of cSLE medicines development. Regulatory requirements so far have been rather consistent when a PIP is agreed, and recommend randomised controlled trials to enable a full benefit-risk assessment. However, PIPs are agreed when adult efficacy data are not yet available and as soon as the product lifecycle progresses, new methods and approaches can offer some advantages over randomised controlled trials in this setting and might provide a comparable level of evidence of efficacy in an alternative way. Extrapolation of adult efficacy data to paediatrics is one possible approach, provided that adult trials produce data that can be used for this purpose and that the degree of residual uncertainty is appropriately quantified for the medicinal product in question. The study also highlights the value of enhanced international cooperation among regulatory authorities, developers, and academic institutions in this field to support collaborative efforts among various stakeholders.<\/jats:p>","DOI":"10.3389\/fmed.2025.1583140","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T05:30:35Z","timestamp":1752125435000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["New medicines for childhood-onset systemic lupus erythematosus: an EU perspective on paediatric drug development"],"prefix":"10.3389","volume":"12","author":[{"given":"Roberto","family":"De Lisa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"de Andres-Trelles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Bax","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Galluzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Alward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Thomson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Karres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermine I.","family":"Brunner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolino","family":"Ruperto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunter F.","family":"Egger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1002\/acr.21757","article-title":"Taxonomy for systemic lupus erythematosus with onset before adulthood.","volume":"64","author":"Silva","year":"2012","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"B2","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s40272-021-00457-z","article-title":"An update on the management of childhood-onset systemic lupus erythematosus.","volume":"23","author":"Trindade","year":"2021","journal-title":"Paediatr Drugs."},{"key":"B3","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/ar4256","article-title":"Update on differences between childhood-onset and adult-onset systemic lupus erythematosus.","volume":"15","author":"Mina","year":"2013","journal-title":"Arthritis Res Ther."},{"key":"B4","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/1756-185X.12419","article-title":"Childhood onset systemic lupus erythematosus: How is it different from adult SLE?","volume":"18","author":"Aggarwal","year":"2015","journal-title":"Int J Rheum Dis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1586\/eci.09.29","article-title":"Childhood- and adult-onset lupus: An update of similarities and differences.","volume":"5","author":"Papadimitraki, Isenberg","year":"2009","journal-title":"Expert Rev Clin Immunol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1097\/00002281-199609000-00016","article-title":"Neonatal lupus.","volume":"8","author":"Buyon","year":"1996","journal-title":"Curr Opin Rheumatol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1159\/000518321","article-title":"Differences in the clinical manifestations and mortality of systemic lupus erythematosus onset in children and adults: A systematic review and meta-analysis.","volume":"183","author":"Huang","year":"2022","journal-title":"Int Arch Allergy Immunol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1136\/annrheumdis-2012-201937","article-title":"Therapeutic approaches for the treatment of renal disease in juvenile systemic lupus erythematosus: An international multicentre PRINTO study.","volume":"72","author":"Miettunen","year":"2013","journal-title":"Ann Rheum Dis."},{"key":"B9","first-page":"424","article-title":"Agreement between multi-dimensional and renal-specific response criteria in patients with juvenile systemic lupus erythematosus and renal disease.","volume":"28","author":"Ruperto","year":"2010","journal-title":"Clin Exp Rheumatol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1136\/annrheumdis-2018-213198","article-title":"Clinical trials in children and adolescents with systemic lupus erythematosus: Methodological aspects, regulatory landscape and future opportunities.","volume":"78","author":"Brunner","year":"2019","journal-title":"Ann Rheum Dis."},{"key":"B11","year":"2006","journal-title":"E. Commission, Regulation (EC) No 1901\/2006 of the European Parliament and of the Council of 12 December 2006 on Medicinal Products for Paediatric use and Amending Regulation (EEC) No 1768\/92, Directive 2001\/20\/EC, Directive 2001\/83\/EC and Regulation (EC) No 726\/2004 Official Journal of the European Union."},{"key":"B12","year":"2025","journal-title":"EPAR - Product Information."},{"key":"B13","year":"2025","journal-title":"EPAR - Product Information"},{"key":"B14","year":"2024","journal-title":"EPAR - Product Information."},{"key":"B15","year":"2015","journal-title":"European Medicines Agency, Guideline on Clinical Investigation of Medicinal Products for the Treatment of Systemic Lupus Erythematosus and Lupus Nephritis EMA\/CHMP\/51230\/2013 corr 2013."},{"key":"B16","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1002\/jcph.2139","article-title":"Extrapolation of adult efficacy data to pediatric systemic lupus erythematosus: Evaluating similarities in exposure-response.","volume":"63","author":"Balevic","year":"2013","journal-title":"J Clin Pharmacol."},{"key":"B17","year":"2024","journal-title":"AdisInsight Drugs."},{"key":"B18","year":"2023","journal-title":"EudraCT Database."},{"key":"B19","doi-asserted-by":"publisher","first-page":"5142","DOI":"10.1093\/rheumatology\/keab140","article-title":"Performance of 2019 EULAR\/ACR classification criteria for systemic lupus erythematosus in a paediatric population-a multicentre study.","volume":"60","author":"Levinsky","year":"2019","journal-title":"Rheumatology (Oxford)."},{"key":"B20","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1002\/acr.24430","article-title":"Performance of the New 2019 European League Against Rheumatism\/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus in Children and Young Adults.","volume":"73","author":"Aljaberi","year":"2019","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1002\/art.40930","article-title":"2019 European league against rheumatism\/American college of rheumatology classification criteria for systemic Lupus Erythematosus.","volume":"71","author":"Aringer","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"S112","DOI":"10.1002\/acr.20623","article-title":"Measures of disease activity and damage in pediatric systemic lupus erythematosus: British Isles Lupus Assessment Group (BILAG), European Consensus Lupus Activity Measurement (ECLAM), Systemic Lupus Activity Measure (SLAM), Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), Physician\u2019s Global Assessment of Disease Activity (MD Global), and Systemic Lupus International Collaborating Clinics\/American College of rheumatology damage index (SLICC\/ACR DI; SDI).","volume":"63","author":"Lattanzi","year":"2011","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"B23","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1002\/art.22002","article-title":"The Pediatric Rheumatology International Trials Organization\/American College of Rheumatology provisional criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus: Prospective validation of the definition of improvement.","volume":"55","author":"Ruperto","year":"2006","journal-title":"Arthritis Rheum."},{"key":"B24","doi-asserted-by":"publisher","first-page":"105523","DOI":"10.1016\/j.jbspin.2023.105523","article-title":"New biologics and targeted therapies in systemic lupus: From new molecular targets to new indications. A systematic review.","volume":"90","author":"Felten","year":"2023","journal-title":"Joint Bone Spine."},{"key":"B25","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1097\/MPG.0000000000001024","article-title":"Use of Placebo in pediatric inflammatory bowel diseases: A position paper from ESPGHAN, ECCO, PIBDnet, and the Canadadian children IBD Network.","volume":"62","author":"Turner","year":"2016","journal-title":"J Pediatr Gastroenterol Nutr."},{"key":"B26","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/pr.2013.66","article-title":"Placebo effects in children: A review.","volume":"74","author":"Weimer","year":"2013","journal-title":"Pediatr Res."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1056\/NEJMoa1205099","article-title":"Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis.","volume":"367","author":"Ruperto","year":"2012","journal-title":"N Engl J Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1136\/annrheumdis-2016-210456","article-title":"Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: Results of a multicentre, double-blind, randomised-withdrawal trial.","volume":"77","author":"Brunner","year":"2018","journal-title":"Ann Rheum Dis."},{"key":"B29","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1002\/art.10072","article-title":"Risk factors for damage in childhood-onset systemic lupus erythematosus: Cumulative disease activity and medication use predict disease damage.","volume":"46","author":"Brunner","year":"2002","journal-title":"Arthritis Rheum."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e031850","DOI":"10.1136\/bmjopen-2019-031850","article-title":"Association between organ damage and mortality in systemic lupus erythematosus: A systematic review and meta-analysis.","volume":"10","author":"Murimi-Worstell","year":"2020","journal-title":"BMJ Open."},{"key":"B31","doi-asserted-by":"publisher","first-page":"e001363","DOI":"10.1136\/lupus-2024-001363","article-title":"Longitudinal associations of flare and damage accrual in patients with systemic lupus erythematosus.","volume":"12","author":"Kandane-Rathnayake","year":"2025","journal-title":"Lupus Sci Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.ejim.2024.08.008","article-title":"Treatment of systemic lupus erythematosus: Analysis of treatment patterns in adult and paediatric patients across four European countries.","volume":"130","author":"Du","year":"2024","journal-title":"Eur J Intern Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"e000817","DOI":"10.1136\/lupus-2022-000817","article-title":"Treatment patterns in paediatric and adult patients with SLE: A retrospective claims database study in the USA.","volume":"10","author":"Brunner","year":"2023","journal-title":"Lupus Sci Med."},{"key":"B34","first-page":"197","author":"Simard","year":"2021","journal-title":"Digital Data in Lupus: Metrics and Future Directions, Outcome Measures and Metrics in Systemic lupus erythematosus."},{"key":"B35","year":"2024","journal-title":"Pediatric Extrapolation E11A ICH."},{"key":"B36","year":"2022","journal-title":"Structured Guidance on the Use of Extrapolation."},{"key":"B37","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/bph.17396","article-title":"Evidence generation throughout paediatric medicines life cycle: Findings from collaborative work between European Medicines Agency (EMA) and EUnetHTA on use of extrapolation.","volume":"182","author":"Karres","year":"2022","journal-title":"Br J Pharmacol."},{"key":"B38","year":"","journal-title":"Assessment Report Benlysta EMA\/547408\/2019 19 September"},{"key":"B39","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1080\/10543406.2023.2170405","article-title":"Perspectives on informative Bayesian methods in pediatrics.","volume":"33","author":"Travis","year":"2023","journal-title":"J Biopharm Stat."},{"key":"B40","year":"2024","journal-title":"Opinions and Letters of Support on the Qualification of Novel Methodologies for Medicine Development."},{"key":"B41","year":"2023","journal-title":"Pediatric Cluster Terms of Reference."},{"key":"B42","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.berh.2013.07.007","article-title":"Paediatric-onset systemic lupus erythematosus.","volume":"27","author":"Malattia","year":"2023","journal-title":"Best Pract Res Clin Rheumatol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s13052-015-0118-6","article-title":"Placebo-controlled trials in pediatrics and the child\u2019s best interest.","volume":"41","author":"Di Pietro","year":"2015","journal-title":"Ital J Pediatr."},{"key":"B44","doi-asserted-by":"publisher","first-page":"2854","DOI":"10.1002\/art.21230","article-title":"The Pediatric Rheumatology International Trials Organization criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus: Prospective validation of the disease activity core set.","volume":"52","author":"Ruperto","year":"2005","journal-title":"Arthritis Rheum."},{"key":"B45","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1002\/acr.23557","article-title":"American college of rheumatology provisional criteria for global flares in childhood-onset systemic Lupus Erythematosus.","volume":"70","author":"Brunner","year":"2018","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"B46","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1002\/acr.23834","article-title":"American College of rheumatology provisional criteria for clinically relevant improvement in Children and adolescents with childhood-onset systemic Lupus Erythematosus.","volume":"71","author":"Brunner","year":"2019","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"B47","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/acr.22651","article-title":"Validation of the Lupus nephritis clinical indices in childhood-onset systemic Lupus Erythematosus.","volume":"68","author":"Mina","year":"2016","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"B48","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1136\/annrheumdis-2011-200106","article-title":"A longitudinal PRINTO study on growth and puberty in juvenile systemic lupus erythematosus.","volume":"71","author":"Rygg","year":"2012","journal-title":"Ann Rheum Dis."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1136\/annrheumdis-2020-217101","article-title":"Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: Results from a randomised, placebo-controlled trial.","volume":"79","author":"Brunner","year":"2020","journal-title":"Ann Rheum Dis."},{"key":"B50","doi-asserted-by":"publisher","first-page":"e001747","DOI":"10.1136\/rmdopen-2021-001747","article-title":"Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: An across-study comparison.","volume":"7","author":"Brunner","year":"2021","journal-title":"RMD Open."},{"key":"B51","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1002\/art.38260","article-title":"Efficacy and safety of abatacept in lupus nephritis: A twelve-month, randomized, double-blind study.","volume":"66","author":"Furie","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1136\/annrheumdis-2021-221478","article-title":"Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis.","volume":"81","author":"Jayne","year":"2022","journal-title":"Ann Rheum Dis."},{"key":"B53","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1186\/s13063-019-3664-1","article-title":"Systematic review of basket trials, umbrella trials, and platform trials: A landscape analysis of master protocols.","volume":"20","author":"Park","year":"2019","journal-title":"Trials."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1056\/NEJMoa1706314","article-title":"Canakinumab for the treatment of autoinflammatory recurrent fever syndromes.","volume":"378","author":"De Benedetti","year":"2018","journal-title":"N Engl J Med."},{"key":"B55","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12969-017-0160-6","article-title":"The new Childhood arthritis and rheumatology research alliance (CARRA) registry: Design, rationale, and characteristics of patients enrolled in the first 12 months.","volume":"15","author":"Beukelman","year":"2017","journal-title":"Pediatr Rheumatol Online J."},{"key":"B56","doi-asserted-by":"publisher","first-page":"109028","DOI":"10.1016\/j.clim.2022.109028","article-title":"Real world treatment of juvenile-onset systemic lupus erythematosus: Data from the UK JSLE cohort study.","volume":"239","author":"Smith","year":"2022","journal-title":"Clin Immunol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1177\/0961203307088006","article-title":"Childhood systemic lupus erythematosus in Latin America. The GLADEL experience in 230 children.","volume":"17","author":"Ram\u00edrez G\u00f3mez","year":"2008","journal-title":"Lupus."},{"key":"B58","year":"2017","journal-title":"State of Paediatric Medicines in the EU 10 years of the EU Paediatric Regulation."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1136\/ard-2022-222858","article-title":"Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus.","volume":"81","author":"van Vollenhoven","year":"2022","journal-title":"Ann Rheum Dis."},{"key":"B60","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1002\/art.42734","article-title":"Kidney Outcomes and Preservation of Kidney Function With Obinutuzumab in Patients With Lupus Nephritis: A Post Hoc Analysis of the NOBILITY Trial.","volume":"76","author":"Rovin","year":"2024","journal-title":"Arthritis Rheumatol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1583140\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T05:30:36Z","timestamp":1752125436000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1583140\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,10]]},"references-count":60,"alternative-id":["10.3389\/fmed.2025.1583140"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1583140","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,10]]},"article-number":"1583140"}}